# A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

> **NCT00587015** · PHASE1 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** CAT-8015

## Key facts

- **NCT ID:** NCT00587015
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-03
- **Final completion:** 2009-10
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** Due to a lack of IP supply and then terminated because they were combined into one new study with the new IP formulation.
- **Last updated:** 2011-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00587015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00587015, "A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00587015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*